← back to ranking

ISRG · Intuitive Surgical, Inc.

Medical - Devices · mkt cap $142.5B · calls: Q1 FY2026 vs Q4 FY2025
53.0 conviction · conf-adj 53

conf –

enthusiasm:24.0 · trend:8 · quantifies:0 · impact:0 · under_radar:5 · credibility:5 · business_impact:8 · commitment:0 · confirmation:3

Enthusiasm latest 8 / prev 5 (rising)

The AI thesis is rising sharply: management moved from digital subscriptions, case insights and possible AI layers in Q4 FY2025 to an explicit AI roadmap in Q1 FY2026 covering anatomy identification, decision support, augmented dexterity, automation and AI-based ROSE. Credibility is supported by proprietary surgical video, kinematic, force and EMR data, but management did not quantify AI revenue, margin, cost, productivity or unit impact.

PAST (realized)
CURRENT (now)
FORWARD (guidance)
TRACK RECORD — PROMISE vs DELIVERY

62/100 track record   delivers  6 calls reviewed

Intuitive makes relatively few hard, dated AI-specific commitments, but the milestone-anchored ones it does make — da Vinci 5 digital-feature clearances and Ion's AI navigation software — have generally landed on schedule, the main slip being Force Feedback's broad availability moving from end-2025 into 2026. Track record skews toward delivering AI capabilities on time via deliberately conservative rollouts.

da Vinci 5 digital features (real-time surgical video review, 3D model review, visual force-feedback gauges) enabled upon 510(k) clearance 'later this year' (2025) — promised Q1 FY2025
delivered Q3 FY2025 received FDA 510(k) clearance adding force gauge, focus mode (in-console video replay) and 3D model viewing — milestone delivered.
Force Feedback (force-sensing) instruments to reach 'broad availability near the end of 2025' — promised Q1 FY2025
partial By Q4 FY2025 still in 'limited launch'; Q1 FY2026 guided broader availability only in Q2 2026 'increasing over the year' — slipped ~2 quarters past the original window.
da Vinci 5 customers to receive software/digital-feature upgrades 'starting this year' (2025), leveraging the 10,000x compute increase — promised Q4 FY2024
delivered Two software updates shipped in 2025 (central config management + force gauge/focus mode; later remote-update foundation) — cadence delivered, though loosely quantified.
Ion AI-based real-time airway navigation / AI CT-scan segmentation as a launched capability — promised Q3 FY2025
delivered Shipped as a cleared software release same period (real-time AI airway navigation, per-scan segmentation, tomosynthesis), with Ion procedures up 51% FY2025; in-market rather than a dated future target.
Longer-term digital/AI roadmap — telesurgery, decision support, augmented dexterity and 'aspects of future automation' — promised Q1 FY2026
too-early Aspirational multi-year roadmap with no number or date; telepresence/My Intuitive+ progressing but automation unquantified — not yet judgeable.
PRICED-IN (REFINED)
MEDIUM

Est. revisions falling  ·  Fwd P/E 46.3  ·  EV/Sales 13.3x

AI claim maps to Instruments and Accessories, Services, Systems

Rating mix has not migrated upward, with strong buys falling from 8 in January to 5 in June, and price targets are lower over the recent month than the quarter and year averages. Forward revenue and EPS estimates still embed solid double-digit growth, but the revision signal is not rising; rising estimates would make AI upside more priced-in, not less. Valuation is rich at 46.3x forward EPS and 13.3x EV/sales, so AI-enabled procedure growth or efficiency flowing through Instruments and Accessories, Services, and Systems is partly reflected despite falling revision momentum.
COVERAGE — ENTHUSIASM TRAJECTORY + CATALYSTS
3Q4 FY20246Q1 FY20256Q2 FY20258Q3 FY20257Q4 FY20259Q1 FY2026

AI enthusiasm across 6 calls — trend ↗ rising

AI evolved from vague digital upgrades to concrete surgical data, navigation, decision support, training, telepresence and future automation roadmap.

RECENT AI CATALYSTS & NEWS
BUSINESS IMPACT - QUALITATIVE MATERIALITY

8/10 qualitative impact   material  medium-term · mixed evidence

Where AI matters: robotic surgery product capability and digital subscriptions

AI is tied directly to Intuitive's core surgical platforms through in-market Ion navigation, da Vinci 5 data capture, case insights, telepresence, anatomy identification, decision support and future automation, so it can affect product differentiation, procedure growth and customer lock-in. The case is still not transformational because management has not quantified revenue, margin or adoption impact and several higher-value capabilities remain roadmap-stage.

Caveats: Regulatory and clinical validation could slow autonomy, decision support or AI-guided anatomy features; No disclosed AI revenue or margin contribution, making near-term P&L impact hard to prove; Surgeon trust, hospital integration and EMR data access may limit scaling; Some key features such as automation and deeper decision support are still aspirational

OPTIONS / MARKET STRUCTURE

option liquidity: good

ATM IV
—
TYPICAL BID-ASK
—
OPEN INTEREST
—

proxy inputs — dollar-ADV $832M · beta 1.509 · px $402.30

source: proxy (no options chain on FMP)
FMP /stable/ exposes no options-chain endpoint on this key, so ATM IV, bid-ask spread and open interest are unavailable. Liquidity below is a PROXY from dollar-ADV, beta and price level (a stand-in for option depth), not measured option-market data.

CONFIRMATION — INSIDERS · 13F · LANGUAGE
Mixed — insiders selling, institutions adding, management language 4/10 measured.
INSIDERS selling 19 open-market sell(s) vs 0 buy(s) — net distribution
INSTITUTIONS (13F) adding as of 2026-03-31: 169 new / 290 closed positions; 1154 increased / 830 reduced; institutional ownership -1.89pp; -119 net 13F holders
MGMT LANGUAGE 4/10 measured Some firm platform/data investment language, but AI impact is framed as long-term roadmap with future capabilities and no quantified business contribution.
commit “da Vinci 5 captures real-world surgical data at greater scale and fidelity”
commit “We continue to invest in the data and digital infrastructure that underpins our longer-term innovation road map.”
hedge “foundational to our long-term digital and AI road map where we expect to add telesurgery, deeper decision support and augmented dexterity”
VERBATIM AI QUOTES
“Turning to our digital ecosystem. We continue to invest in the data and digital infrastructure that underpins our longer-term innovation road map.”
— David Rosa, Q1 FY2026
“da Vinci 5 captures real-world surgical data at greater scale and fidelity, enabling deeper insight into how procedures are performed in practice.”
— David Rosa, Q1 FY2026
“That insight paired with clinical context from connected electronic medical records, provides better understanding of variation, workflow and outcomes, and informs current and planned digital and AI-enabled capabilities.”
— David Rosa, Q1 FY2026
“Collectively, these efforts are foundational to our long-term digital and AI road map where we expect to add telesurgery, deeper decision support and augmented dexterity, including aspects of future automation, all in pursuit of advancing the Quintuple Aim.”
— David Rosa, Q1 FY2026
“Over the midterm, SP will incorporate much of the da Vinci 5 ecosystem, including current and future digital and AI capabilities.”
— David Rosa, Q1 FY2026
“We see opportunities to continue to drive innovation-led revenue performance with our SP stapler, planned SP vessel sealer and growth in use of existing and planned AI and digital capabilities.”
— Jamie Samath, Q1 FY2026
“We also have plans to increase the value of our Ion platform in the lung through our pursuit of a staging indication and the integration of AI-based ROSE technology.”
— Jamie Samath, Q1 FY2026
“And we believe, yes, that AI will be a contributor to moving the Quintuple Aim forward.”
— David Rosa, Q1 FY2026
“And it starts with high-quality data, and that data will exist in video data from surgeries. It will exist in robotic data streams like kinematic data and force data. It will exist in connected electronic medical records, where we're working with customers to do so.”
— David Rosa, Q1 FY2026
“Some will be as operational guidance and assistance as they look at their hospital robotic program and want to increase efficiencies or understand costs.”
— David Rosa, Q1 FY2026
“An example of this kind of first phase might be AI-enabled anatomy identification where you can see AI showing critical structures in the surgical field, showing tissue planes to help assist the surgeon.”
— David Rosa, Q1 FY2026
“Then, over time, what we expect is that many of those same foundations that are being established and built in kind of that first phase, if you will, will support more advanced assistance around augmented dexterity and it will include -- likely include aspects of automation.”
— David Rosa, Q1 FY2026
“Our advantage, we believe, lies is in the unique data sets that are available to us today through something like Force Feedback and will be increasingly available to us as we add capability to da Vinci 5.”
— David Rosa, Q1 FY2026
“My Intuitive+, our digital subscription package offered with da Vinci 5 includes simulation, telecollaboration and case insights and is designed to help customers understand their surgical performance, collaborate in real time and receive personalized training recommendations.”
— David Rosa, Q4 FY2025
“Surgeons are now able to more easily tap into the collective knowledge of the da Vinci community through real-time case observation, collaboration and mentoring.”
— David Rosa, Q4 FY2025
“Those molecules will have revenue streams attached to them.”
— David Rosa, Q4 FY2025
“All of those are pointed at trying to give more information to the surgeon and to the system where we're able to add perhaps some AI layers to it, but really with the intent of improving -- ultimately improving outcomes, be it in prostate cancer or ureteral injuries or perhaps in areas of surgery where perfusion, which is where the tissue oxygenation is pointed, can make a difference in outcomes.”
— David Rosa, Q4 FY2025
“With respect to the case insights portion of that package, we've got good early customer feedback.”
— Jamie Samath, Q4 FY2025
“Come Q2-ish of '26, then customers now have the opportunity to renew for that subscription package where they'll now have to pay.”
— Jamie Samath, Q4 FY2025
“And in the end, then the value that surgeons and the customers are experiencing with that package would determine both what is the renewal rate and what is the ASP that we realize.”
— Jamie Samath, Q4 FY2025
ANALYST QUESTIONS ON AI
Q (Q1 FY2026, Travis Steed): Maybe to start, I kind of want to talk a little bit about some of the future. You talked a lot about data and digital infrastructure, augmented dexterity. Just kind of curious how you see the digital and data road map for Intuitive. And there's also some hints on biopsy and the ROSE acquisition. So I'd love to kind of hear your big picture view of how that kind of plays out and anything you can say on timing?
A: So I'll start with AI. And I'm really -- and you asked the question, but I'm going to speak specifically about AI as it shows up in our products and with our customers and not so much AI on the corporate side.
Q (Q1 FY2026, Travis Steed): And there's also some hints on biopsy and the ROSE acquisition. So I'd love to kind of hear your big picture view of how that kind of plays out and anything you can say on timing?
A: So Travis, real quick, you had asked about ROSE and EBUS and just some color there. So both are known technologies. And the time lines are more short term, but they won't be this year.
Q (Q4 FY2025, Travis Steed): And you've talked a lot on advanced imaging. Just curious how you think about incorporating these additional advanced imaging features into the robotic ecosystem? Did you leverage the existing hardware? Or is there a new hardware? How do you think about recognizing the value of the -- that you're providing to customers? Is it just deeper penetration? Or is there a potential for new revenue streams? Just want to try to understand like how some of this imaging stuff could come into the business in a more detailed way.
A: All of those are pointed at trying to give more information to the surgeon and to the system where we're able to add perhaps some AI layers to it, but really with the intent of improving -- ultimately improving outcomes, be it in prostate cancer or ureteral injuries or perhaps in areas of surgery where perfusion, which is where the tissue oxygenation is pointed, can make a difference in outcomes.
Q (Q4 FY2025, Frederick Wise): Dave, you also highlighted digital subscription. And I'm just not sure if I've personally, maybe I've missed it, heard that language, it sounds like a positive economic factor and something potentially incremental. Again, could you just expand on your comments and what it might mean to the growth outlook or adoption of da Vinci 5, et cetera?
A: So David was referring to MIA+, which comes with da Vinci 5, it incorporates Telepresence, integrated skill simulation and case insights.
Q (Q4 FY2025, Patrick Wood): So is it a lower form factor? Or is it getting the tech to the point where automation and speed is just better than LAP anyway?
A: If we focus on, let's say, the ASC setting, I'd go back to what we described before and say, what is required there is great clinical outcomes, routine use, repeatable use, reliability, those parts, the needs there that exist, I think, are really well served by the existing ecosystem that we have today.